Skip to Content
Merck
CN

32144

Supelco

Clinafloxacin

VETRANAL®, analytical standard

Synonym(s):

7-(3-Amino-1-pyrrolidinyl)-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydroxy-4-oxo-3-quinolinecarboxylic acid

Sign Into View Organizational & Contract Pricing

Select a Size

About This Item

Empirical Formula (Hill Notation):
C17H17ClFN3O3
CAS Number:
105956-97-6
Molecular Weight:
365.79
MDL number:
MFCD00865120
UNSPSC Code:
41116107
PubChem Substance ID:
329754065
NACRES:
NA.24

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

grade

analytical standard

Quality Level

100

product line

VETRANAL®

technique(s)

HPLC: suitable
gas chromatography (GC): suitable

application(s)

forensics and toxicology
veterinary

format

neat

storage temp.

2-8°C

SMILES string

NC1CCN(C1)c2c(F)cc3C(=O)C(=CN(C4CC4)c3c2Cl)C(O)=O

InChI

1S/C17H17ClFN3O3/c18-13-14-10(5-12(19)15(13)21-4-3-8(20)6-21)16(23)11(17(24)25)7-22(14)9-1-2-9/h5,7-9H,1-4,6,20H2,(H,24,25)

InChI key

QGPKADBNRMWEQR-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

General description

Clinafloxacin is a fluoroquinolone antibiotic with a broad range of bactericidal activity, used in the treatment of gynaecologic and urinary infections. It inhibits bacterial DNA gyrase enzyme which is responsible for synthesis, replication, repair and transcription.

Application

Clinafloxacin may be used as a reference standard for the determination of clinafloxacin in urine samples of rat and human by capillary zone electrophoresis.
Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.

Legal Information

VETRANAL is a registered trademark of Merck KGaA, Darmstadt, Germany

Pictograms

Health hazard
GHS08

Signal Word

Warning

Hazard Statements

H361d

Precautionary Statements

P281

Hazard Classifications

Repr. 2

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
BCBV5926

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Rapid HPLC assay of clinafloxacin, fleroxacin, levofloxacin, sparfloxacin and tosufloxacin.
Lyon DJ, et al.
The Journal of Antimicrobial Chemotherapy, 34(3), 446-448 (1994)
E J Goldstein
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 23 Suppl 1, S25-S30 (1996-12-01)
The currently available fluoroquinolones have modest activity against anaerobes. Newer fluoroquinolones with increased in vitro activity against anaerobes are under development and include levofloxacin, clinafloxacin, sparfloxacin, trovafloxacin, grepafloxacin, and DU-6859a. Side effects of the quinolones have varied according to the
A Domenech et al.
Microbial drug resistance (Larchmont, N.Y.), 9 Suppl 1, S53-S59 (2003-11-25)
The increasing incidence of ciprofloxacin resistance in Streptococcus pneumoniae may limit the efficacy of the new quinolones in difficult-to-treat infections such as meningitis. The aim of the present study was to determine the efficacy of clinafloxacin alone and in combination
Yan Wang et al.
Bioorganic & medicinal chemistry letters, 22(17), 5363-5366 (2012-08-14)
A series of clinafloxacin triazole hybrids as a new type of antibacterial and antifungal agents were synthesized for the first time and screened for their antimicrobial efficacy against four Gram-positive bacteria, four Gram-negative bacteria and two fungi by two fold
J M Sierra et al.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 11(9), 750-758 (2005-08-18)
Two quinolone-susceptible Staphylococcus aureus and five quinolone-susceptible Streptococcus pneumoniae isolates were used to obtain in-vitro quinolone-resistant mutants in a multistep resistance selection process. The fluoroquinolones used were ciprofloxacin, moxifloxacin, levofloxacin, gemifloxacin, trovafloxacin and clinafloxacin. The mutagenicity of these quinolones was
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service